Clearfield (CLFD) Q2 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 day and welcome to the Clearfield Fiscal Second Quarter twenty twenty five Conference Call. All participants will be in a listen only mode. A brief question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Greg McNiff, Investor Relations for Clearfield. Please go ahead. Speaker1 Thank you. Joining me on today's call are ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $143.5 million, representing approximately 48% year-over-year growth and 18% sequential growth from Q4 2024 [7] - TransMedics' transplant services revenue for Q1 was approximately $55.3 million, up from $35.5 million in Q1 2024, reflecting approximately 56% year-over-year growth and 18.5% sequential growth [8] - Operating profit for Q1 was $27.4 million, representing approximately 19% of total revenue, up from $8.6 million or 7% of total revenue in Q4 2024 [8][22] - Net income for the quarter was $25.7 million, representing a 111% year-on-year increase and 275% sequentially [23] - Earnings per share were $0.76, and diluted earnings per share were $0.70 for Q1 2025 [25] Business Line Data and Key Metrics Changes - U.S. transplant revenue was $139 million, up 51% year-over-year and 19% sequentially, with liver contributing $109 million, heart $26 million, and lung $4 million [19] - Product revenue for Q1 reached $88 million, up 44% year-over-year and 18% sequentially, driven by increased organ utilization in liver and continued OCS adoption [20] - Transplant logistics services revenue for Q1 was $26.1 million, representing approximately 80% year-over-year and 20% sequential growth [9] Market Data and Key Metrics Changes - The company achieved a new high watermark for overall case volume in Q1 2025, indicating strong market demand [7] - The average daily aircraft availability was approximately 15.4, up from 14 in Q4 2024, covering 78% of NOP emissions requiring air transport [9] Company Strategy and Development Direction - The company plans to launch two new heart and lung clinical programs later in 2025 to catalyze growth in 2026 and beyond [10] - A strategic plan to open a disposable design center of excellence and a new manufacturing facility in Mirandola, Italy, aims to leverage local expertise and ensure business continuity [14][95] - The company is focused on vertically integrating critical technology blocks to minimize supply chain risks [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining momentum throughout 2025, despite potential quarterly variability and seasonality [17][26] - The company raised its full-year 2025 revenue guidance to between $565 million and $585 million, reflecting approximately 28% to 32% growth over 2024 [17][25] - Management believes organ transplantation is largely insulated from economic cycles due to its lifesaving nature and cost-effectiveness [16] Other Important Information - Total operating expenses for Q1 were approximately $61 million, up 28% year-over-year, primarily driven by a 51% increase in R&D [22] - The company ended the quarter with $310 million in cash, down $26.5 million from the end of 2024 [24] Q&A Session Summary Question: What are the main drivers of growth in liver? - Management highlighted increased utilization of deceased donors across both DVD and DCD, gaining share and momentum in the liver platform [34][36] Question: What is the outlook for April and beyond? - Management indicated confidence in maintaining momentum but acknowledged potential variability between quarters [37][38] Question: How will clinical trials impact product and service margins? - Management expressed confidence in incurring product revenue during trials but remained cautious about service revenue on the control arm [42] Question: What is the impact of competitors entering the liver market? - Management emphasized the superior results of the OCS Liver platform and the need for competitors to prove their value [44][46] Question: What is the reason for the increase in receivables? - Management attributed the increase to the timing of billing and expected recovery in Q2 [53][54] Question: How does the company view pricing in a competitive environment? - Management stated that the focus should be on the value delivered rather than pricing, emphasizing the economic efficiency of their technology [62][65] Question: What are the expectations for operating margin expansion? - Management indicated that the majority of operating margin increases would be driven by gains in operating leverage, with planned investments for later in the year [69] Question: What is the rationale for opening a facility in Mirandola, Italy? - Management noted that Mirandola is a hub for perfusion technologies and offers significant engineering talent necessary for their products [95][96]

Owlet (OWLT) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Thank you for your patience. Whilst you're waiting for the start of today's call with Outlook, I would like to remind you that it's star followed by 1 to join the queue for a question today. And if you would like to remove that request at any point, you can do so by using followed by 2. And if you need operator assistance at any point during today's call, please press then 0. Thank you. Today's host will be Jay Zenzo, investor relations of ...

Clean Energy Fuels (CLNE) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good day, everyone, and welcome to today's Clean Energy Fuels First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask questions during the question and answer session. Please note this call may be recorded and I will be standing by should you need any assistance. It is now my pleasure to turn the conference over to Robert F ...

ICU Medical (ICUI) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good day, and welcome to the ICU Medical Inc. First Quarter twenty twenty five Earnings Conference Call. All participants will be in a listen only mode. After today's presentation, there will be opportunity to ask questions. Please note today's event is being recorded. I'd like to now turn the conference over to John Mills. Please go ahead. Speaker1 Thank you. Good afternoon, everyone. Thank you for joining us to discuss ICU Medical' ...

TELA Bio (TELA) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good afternoon, ladies and gentlemen, and welcome to the TELA Bio First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in listen only mode. Following the prepared remarks, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Louisa Smith from Gilmartin Group. Speaker1 Thank you, Gerald, and good a ...

Sight Sciences Inc (SGHT) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the SITE Sciences first quarter two thousand twenty five earning results conference call. At this time, all participants are in listen only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you will need to press 11 on your telephone. You would then hear an automated message advising your hand is raised ...

Pulse Biosciences (PLSE) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good afternoon, ladies and gentlemen, and welcome to the Pulse Biosciences First Quarter twenty twenty five Financial Results Conference Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press 0 for the operator. This call is being recorded on Thursday, 05/08/2025. I would like ...

Skye Bioscience (SKYE) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Ladies and gentlemen, thank you for standing by. My name is JL, and I will be your conference operator today. At this time, I would like to welcome everyone to the Sky BioScience First Quarter Fiscal twenty twenty five Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. I would now like to turn the conference over to Bernie He ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 increased to $1,577,000, up from $1,114,000 in Q1 2024, representing a 42% increase driven by heightened demand for bit solutions and mobile systems [11] - Product-based revenues totaled $1,000,000 in Q1 2025, reflecting a 35% growth compared to Q1 2024 [11] - Service revenues generated $577,000, a 56% increase from the same prior year period [11] - BIT solution sales reached approximately $300,000, marking nearly a 200% increase from just over $100,000 in Q1 2024 [12] - Operating loss for the quarter was approximately $754,000, an improvement from the operating loss of $1,226,000 in the same quarter last year [12] - Net loss was approximately $256,000 or $0.01 per share compared to $1,310,000 or 7% loss per share in the prior year [12] - Cash and cash equivalents stood at approximately $674,000, with working capital of $3,800,000 [13] Business Line Data and Key Metrics Changes - Total sales in February 2025 saw a 42% increase compared to February 2024, with a 21% increase in April 2025 compared to April 2024 [6] - Year-to-date, there was a 169% surge in bit solution sales compared to the same period last year [6] - The company welcomed several new customers, including a division of the US Army and a children's hospital, indicating expansion in various sectors [8] Market Data and Key Metrics Changes - The company reported an increase in open sales log from approximately $877,000 at the end of 2024 to $1,600,000 by the end of Q1 2025 [10] - The IHP corporate service deployment pipeline currently stands at $1,000,000 in open proposals for 2025 [22] Company Strategy and Development Direction - The company is focused on expanding its product line and distribution strategy, with new service offerings launched in 2024 [5] - There is a commitment to educating the market on the importance of protective disinfection through the SteraMist Pro certified program [7] - The company aims to enhance its sales infrastructure by establishing new distribution channels and recruiting qualified business developers [21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about sustaining sales momentum and anticipated a positive trend in sales throughout the year [14] - The company is encouraged by significant progress made in Q1 2025, showcasing the effectiveness of its strategies and product offerings [23] - Management noted that they are not experiencing significant problems due to government budget cuts and expect increased demand from government sectors [28] Other Important Information - The company is actively seeking strong global partners and is focused on rebuilding brand presence in various international markets [21] - The partnership with AlgaFeed has opened a new aquaculture market for SteriMist IHP [8] Q&A Session Summary Question: Do you have any financial goals for the year 2025? - Management is confident that 2025 will be a great year and expects to improve on last year's numbers [25] Question: Do you anticipate any effects from the tariffs trade policy? - Management indicated that they have had minor issues with tariffs but are not experiencing significant problems with international sales [26][27] Question: Do you anticipate significant problems due to government budget cuts? - Management believes there will be an increase in demand from government sectors that utilize their products [28] Question: Any new developments on food safety? - Management reported a surge in interest and requests related to food safety, indicating a growing market [30] Question: Any updates on SteraMist for prevention of bird flu transmission? - Management noted that there is increased interest in using their products for bird flu disinfection, but no significant developments have materialized recently [31][32] Question: Any new developments on Ceramist as an ethylene oxide replacement? - Management confirmed ongoing negotiations with companies looking to replace ethylene oxide with Ceramist [33] Question: Was the order for treating pacemakers used in replacement of ethylene oxide? - The order was not a replacement but helped develop a new protocol for the medical device manufacturer [34][35] Question: Have any new ways been developed to educate the market? - The SteraMist Pro certified program was launched to educate the market and improve product usage [37][38]